AstraZeneca Expands Coppell Manufacturing Facility for Lokelma

AstraZeneca has unveiled its newly expanded, state-of-the-art manufacturing facility in Coppell, Texas, marking a major milestone in the company’s commitment to strengthen U.S. manufacturing and global medicine supply. This investment will double production of Lokelma, benefiting patients in the United States and more than 50 countries worldwide.

The expansion adds a new 9,000-square-foot building with two advanced manufacturing lines, enhanced laboratory testing capabilities, additional warehousing, and expanded administrative space. The Coppell site, which employs over 250 people, remains AstraZeneca’s sole global manufacturing location for Lokelma.

This project follows the groundbreaking at AstraZeneca’s Albemarle County, Virginia facility and is part of the company’s broader investment in U.S. R&D and manufacturing over the next five years—reinforcing its commitment to innovation, quality, and patient access to critical medicines.

Learn more